Category: Pα+ - Page 3 - Psychedelic Alpha

Read more about the article FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies

Post published:May 19, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish

Pα+ Psychedelic Bulletin #197: Portuguese Health-Related Professions Unite on Psychedelics; Shrooms, Shots, and the Next Surgeon General; Religious Leaders Study Set to Publish

Post published:May 16, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down

Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down

Post published:May 13, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on Psychedelics Plans

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on Psychedelics Plans

Post published:May 9, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, Bitcoin

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business of Psychedelics, Bitcoin

Post published:May 2, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout

March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout

Post published:May 1, 2025
Post category:Psychedelic Patent Analysis Pα+

Read more about the article Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona

Pα+ Psychedelic Bulletin #194: Make-or-Break Moment Looms for Compass; RFK Jr. Discusses LSD Use; Europe’s Next Chapter in Psychedelic Therapy Begins in Barcelona

Post published:April 25, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Psychedelic Funding Update: Q1 2025

Psychedelic Funding Update: Q1 2025

Post published:April 22, 2025
Post category:Analysis Pα+

Read more about the article Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride

Post published:April 18, 2025
Post category:Interviews Pα+

Read more about the article Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-Ups

Pα+ Psychedelic Bulletin #193: VA Secretary on Psychedelics; Preprint Challenges Replicability of Psilocybin’s Persistent Effects in Mice; Market Mayhem and Agency Shake-Ups

Post published:April 11, 2025
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.